Pulse Biosciences (NASDAQ:PLSE - Get Rating) had its price objective lowered by stock analysts at Stephens from $14.00 to $12.00 in a research report issued on Friday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Stephens' target price suggests a potential upside of 146.91% from the stock's previous close.
https://www.marketbeat.com/instant-alerts/nasdaq-plse-a-buy-or-sell-right-now-2022-04/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.